GSK plc (LSE/NYSE) has confirmed it has reached a confidential settlement with Boyd/Steenvoord, resolving the case filed in California state court.
The case, which was set to begin trial on 2 April 2024, will be dismissed. The settlement reflects the Company’s desire to avoid the distraction related to protracted litigation in this case.
GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.
